MetaCap

Alvotech (ALVO) vs Taysha Gene Therapies (TSHA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Taysha Gene Therapies (TSHA) has outperformed Alvotech (ALVO) over the past year, losing 11.2% versus a loss of 19.8%. Alvotech is the larger company by market cap ($1.47 billion vs $1.21 billion), about 1.2 times the size. Alvotech converts more of its revenue into profit, with a net margin of 4.8% versus -1115.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALVO-19.84%TSHA-11.22%
+72%+12%-47%
Nov 21, 20251 yearNov 20, 2026
ALVO-57.53%TSHA+32.38%
+153%+33%-88%
Jun 13, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALVO versus TSHA key metrics
MetricALVOTSHA
Share price$4.12$3.72
Market cap$1.47B$1.21B
1-day change-3.96%-1.33%
YTD return-19.69%-32.36%
1-year return-19.84%-11.22%
5-year return—-70.69%
Forward P/E19.46—
EPS (TTM)$-0.82$-0.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$586.32M$9.77M
Revenue growth (YoY)+19.74%+17.28%
Net income (latest FY)$27.92M$-109.00M
Gross margin59.82%—
Operating margin13.34%-1130.65%
Net margin4.76%-1115.27%
52-week high$6.53$7.30
52-week low$2.94$3.46
Distance from 52-week high-36.91%-49.04%
Analyst consensusbuystrong_buy
Avg. price target upside+82.04%+249.46%
Average volume1.13M3.59M
Shares outstanding356.82M326.05M
Employees1,27999
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Alvotech is more profitable, keeping 4.8 cents of every revenue dollar as net income versus -1115.3 cents for Taysha Gene Therapies.

About Alvotech

ALVO stock →

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,279 employees

About Taysha Gene Therapies

TSHA stock →

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 99 employees

ALVO vs TSHA FAQ

Which is bigger, Alvotech or Taysha Gene Therapies?

Alvotech (ALVO) is larger, with a market capitalization of $1.47B compared with $1.21B for Taysha Gene Therapies (TSHA).

Which stock has performed better over the past year, ALVO or TSHA?

TSHA returned -11.22% over the past 12 months, compared with -19.84% for ALVO (price return, excluding dividends). Past performance does not predict future results.

Are Alvotech and Taysha Gene Therapies in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons